Showing 1851-1860 of 4355 results for "".
Financial Benchmarking Update for Dermatology Practices
https://practicaldermatology.com/topics/practice-management/financial-benchmarking-update-for-dermatology-practices/21621/Successful practices use benchmarking to compare their performance to others, assess their own performance over time, and plan for the long term.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21848/Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuBiologics and Beyond
https://practicaldermatology.com/topics/psoriasis/biologics-and-beyond/23554/A look at off-label use of biologics and JAK inhibitors.Who's Afraid of the Big Black Box?
https://practicaldermatology.com/topics/psoriasis/whos-afraid-of-the-big-black-box/20286/Physician Spotlight
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight/20685/Practicing picture-perfect dermatology.Melanoma and the Predictive Value of Nevi: Unexpected Findings?
https://practicaldermatology.com/topics/practice-management/melanoma-and-the-predictive-value-of-nevi-unexpected-findings/20936/A new analysis shows that the association between nevi and melanoma is complex.Raising Issues with MOC
https://practicaldermatology.com/topics/practice-management/raising-issues-with-moc/21195/Dermatologists and the AAD speak out against current MOC requirements and suggest changes.The Melanoma Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-melanoma-pipeline/21400/A closer look at the latest data for two investigational agents that have made headlines.